Triple therapy for the management of COPD: a review (Q37868010)

24 August 2017

0 references

1 reference

title

Triple therapy for the management of COPD: a review (English)

1 reference

24 August 2017

Kathryn Gaebel

1

1 reference

24 August 2017

R Andrew McIvor

2

1 reference

24 August 2017

Feng Xie

3

1 reference

24 August 2017

Gord Blackhouse

4

1 reference

24 August 2017

Diana Robertson

5

1 reference

24 August 2017

Nazila Assasi

6

1 reference

24 August 2017

Paul Hernandez

7

1 reference

24 August 2017

Ron Goeree

8

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 April 2011

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

3

1 reference

24 August 2017

206-243

1 reference

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

24 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Prevalence of COPD: first epidemiological study of a large region in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

COPD prevalence in southeastern Kentucky: the burden of lung disease study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

The prevalence of airflow obstruction in rural primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Targeting the COPD exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Resource use and risk factors in high-cost exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Tiotropium and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Allocation concealment in randomised trials: defending against deciphering

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Longitudinal changes in the nature, severity and frequency of COPD exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2011.560131

10.3109/15412555.2011.560131

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference